{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:42:43Z","timestamp":1792032163396,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.schres.2024.07.028","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:26:51Z","timestamp":1722950811000},"page":"371-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"271","author":[{"given":"Qi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyue","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2024.07.028_bb0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000064807","article-title":"Atypical antipsychotic drug use and diabetes","volume":"71","author":"Ananth","year":"2002","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.schres.2024.07.028_bb0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pharmthera.2022.108236","article-title":"Clozapine\u2019s multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia","volume":"236","author":"Bartolomeis","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"1\u20133","key":"10.1016\/j.schres.2024.07.028_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2009.04.003","article-title":"Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study","volume":"111","author":"Chien","year":"2009","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2024.07.028_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/acps.12989","article-title":"Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study","volume":"139","author":"Cho","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.schres.2024.07.028_bb0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.euroneuro.2005.09.003","article-title":"Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment","volume":"16","author":"Cohen","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2024.07.028_bb0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.MY20096AH1C","article-title":"Treatment-resistant schizophrenia: definition, predictors, and therapy options","volume":"82","author":"Correll","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2024.07.028_bb0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.schres.2024.07.028_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","article-title":"Prevalence and correlates of diabetes in national schizophrenia samples","volume":"26","author":"Dixon","year":"2000","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2024.07.028_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00561782","article-title":"Effect of chlorpromazine on blood glucose and plasma insulin in man","volume":"11","author":"Erle","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2024.07.028_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14656566.2018.1543409","article-title":"Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment","volume":"20","author":"Faden","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"issue":"Suppl. 23","key":"10.1016\/j.schres.2024.07.028_bb0060","first-page":"39","article-title":"Clozapine: diabetes mellitus, weight gain, and lipid abnormalities","volume":"62","author":"Henderson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.07.028_bb0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00023210-200216020-00001","article-title":"Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?","volume":"16","author":"Henderson","year":"2002","journal-title":"CNS Drugs"},{"issue":"7414","key":"10.1016\/j.schres.2024.07.028_bb0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"10202","key":"10.1016\/j.schres.2024.07.028_bb0075","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.07.028_bb0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuropharm.2018.07.030","article-title":"Abnormalities in behaviour, histology and prefrontal cortical gene expression profiles relevant to schizophrenia in embryonic day 17 MAM-exposed C57BL\/6 mice","volume":"140","author":"Huo","year":"2018","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.schres.2024.07.028_bb0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.07.028_bb0095","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.1092","article-title":"Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims","volume":"14","author":"Lambert","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3","key":"10.1016\/j.schres.2024.07.028_bb0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/JCP.0000000000001671","article-title":"Long-term outcome of clozapine in treatment-resistant schizophrenia","volume":"43","author":"Lee","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"22","key":"10.1016\/j.schres.2024.07.028_bb0105","first-page":"3497","article-title":"Regression analysis of risk factors related to antipsychotics-induced diabetes mellitus","volume":"42","author":"Liu","year":"2020","journal-title":"Hebei Medical J."},{"issue":"4","key":"10.1016\/j.schres.2024.07.028_bb0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.13105\/wjma.v5.i4.80","article-title":"Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale","volume":"5","author":"Luchini","year":"2017","journal-title":"World J. Meta-Anal."},{"issue":"6","key":"10.1016\/j.schres.2024.07.028_bb0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2024.07.028_bb0120","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2024.07.028_bb0125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0010-440X(96)90054-1","article-title":"Diabetes mellitus in schizophrenic patients","volume":"37","author":"Mukherjee","year":"1996","journal-title":"Compr. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2024.07.028_bb0130","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2024.07.028_bb0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/acps.12954","article-title":"Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis","volume":"138","author":"Okhuijsen-Pfeifer","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2024.07.028_bb0140","first-page":"5","article-title":"Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia","volume":"6","author":"Ollendorf","year":"2004","journal-title":"MedGenMed"},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2024.07.028_bb0145","doi-asserted-by":"crossref","first-page":"B82","DOI":"10.2337\/diacare.27.suppl_2.B82","article-title":"Development of evidence-based clinical practice guidelines for diabetes: the Department of Veterans Affairs\/Department of Defense guidelines initiative","volume":"27","author":"Pogach","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2024.07.028_bb0150","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1016\/S0924-9338(05)80189-0","article-title":"Schizophrenia and diabetes: epidemiological data","volume":"20","author":"Rouillon","year":"2005","journal-title":"Eur. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.07.028_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/acps.13111","article-title":"How and when to use clozapine","volume":"141","author":"Rubio","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.schres.2024.07.028_bb0160","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 10","key":"10.1016\/j.schres.2024.07.028_bb0165","first-page":"31","article-title":"Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials","volume":"60","author":"Stahl","year":"1999","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2024.07.028_bb0170","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.schres.2024.07.028_bb0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/070674370304800512","article-title":"Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia","volume":"48","author":"Subramaniam","year":"2003","journal-title":"Can. J. Psychiatr."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2024.07.028_bb0180","first-page":"90","article-title":"Characteristics of diabetes mellitus in schizophrenic patients","volume":"70","author":"Tabata","year":"1987","journal-title":"J. Med. Assoc. Thail."},{"issue":"5","key":"10.1016\/j.schres.2024.07.028_bb0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2024.07.028_bb0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.07.028_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08039488.2020.1811374","article-title":"Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia","volume":"75","author":"Verma","year":"2021","journal-title":"Nord. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2024.07.028_bb0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2024.07.028_bb0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pds.1781","article-title":"The incidence of diabetes in atypical antipsychotic users differs according to agent\u2014results from a multisite epidemiologic study","volume":"18","author":"Yood","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"24","key":"10.1016\/j.schres.2024.07.028_bb0210","first-page":"154","article-title":"Treatment and related analysis of diabetes caused by antipsychotic drugs","volume":"8","author":"Zhao","year":"2014","journal-title":"Good Health for All"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424003347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424003347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T14:26:02Z","timestamp":1725719162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424003347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":40,"alternative-id":["S0920996424003347"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.07.028","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}